DOI:
10.1055/s-00000059
Pneumologie
LinksClose Window
References
Baas P, Scherpereel A, Nowak AK. et al.
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
The Lancet 2021;
397: P375-386
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.